Dr. Mei has been one of the key management members of our Group and has been actively involved in the business, strategy and operational management of our Group since its establishment.
Dr. Mei has over 25 years of experience in clinical research and development of oncology therapeutics globally and has successfully led the development of multiple oncology products. He has published over 70 publications and holds multiple patents jointly with other inventors. In the 1990s, Dr. Mei dedicated himself to extensive cancer research at the National Cancer Institute in the United States as a staff fellow. In February 2001, Dr. Mei joined as a principal scientist in the oncology team in the drug discovery division and an associate director at Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. From April 2006 to October 2008, Dr. Mei worked as a senior director at Novartis Oncology, part of the Innovative Medicines division of Novartis AG. From October 2008 to March 2017, he served as an executive director of the clinical development department at Celgene (now part of Bristol-Myers Squibb). Dr. Mei has been a director of Jiangsu Asieris Pharmaceuticals Co., Ltd. since November 2014. Dr. Mei was involved in the management of Antengene Zhejiang since April 2017. In addition, Dr. Mei currently holds an adjunct professorship at the Baruch S. Blumberg Institute.
Dr. Mei received his Doctor of Medicine degree in medicine from Hunan Medical University (now XiangYa School of Medicine of Central South University) in July 1989. Dr. Mei obtained his Doctor of Philosophy degree in pharmacology and toxicology from the University of Maryland in January 1994. Dr. Mei was a member of the American Society of Clinical Oncology and has also been a member of the American Society of Hematology since 2006.